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Background: An early report on the molecular subtyping of muscle-invasive bladder
cancer (MIBC) by gene expression suggested that response to neoadjuvant chemothera-
py (NAC) varies by subtype.
Objective: To investigate the ability of molecular subtypes to predict pathological
downstaging and survival after NAC.
Design, setting, and participants: Whole transcriptome profiling was performed on pre-
NAC transurethral resection specimens from 343 patients with MIBC. Samples were
classified according to four published molecular subtyping methods. We developed a
single-sample genomic subtyping classifier (GSC) to predict consensus subtypes (clau-
din-low, basal, luminal-infiltrated and luminal) with highest clinical impact in the
context of NAC. Overall survival (OS) according to subtype was analyzed and compared
with OS in 476 non-NAC cases (published datasets).
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Outcome measurements and statistical analysis: Receiver-operating characteristics were
used to determine the accuracy of GSC. The effect of GSC on survival was estimated by Cox
proportional hazard regression models.
Results and limitations: The models generated subtype calls in expected ratios with high
concordance across subtyping methods. GSC was able to predict four consensus molecular
subtypes with high accuracy (73%), and clinical significance of the predicted consensus
subtypes could be validated in independent NAC and non-NAC datasets. Luminal tumors
had the best OS with and without NAC. Claudin-low tumors were associated with poor OS
irrespective of treatment regimen. Basal tumors showed the most improvement in OS with
NAC compared with surgery alone. The main limitations of our study are its retrospective
design and comparison across [14_TD$DIFF]datasets.
Conclusions: Molecular subtyping may have an impact on patient benefit to NAC. If
validated in additional studies, our results suggest that patients with basal tumors should
be prioritized for NAC. We discovered the first single-sample classifier to subtype MIBC,
which may be suitable for integration into routine clinical practice.
Patient summary: Different molecular subtypes can be identified in muscle-invasive
bladder cancer. Although cisplatin-based neoadjuvant chemotherapy improves patient
outcomes, we identified that the benefit is highest in patients with basal tumors. Our
newly discovered classifier can identify these molecular subtypes in a single patient and
could be integrated into routine clinical practice after further validation.
# 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Please visit www.eu-acme.org/
europeanurology to read and
answer questions on-line.
The EU-ACME credits will
then be attributed
automatically.
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Neoadjuvant cisplatin-based chemotherapy (NAC) is the
standard treatment in muscle-invasive bladder cancer
(MIBC) prior to radical cystectomy [1–3]. Although NAC
improves pathological downstaging and[5_TD$DIFF] patient survival,
only approximately 40% of patients experience a major
response, defined as absence of muscle-invasive disease and
lymph node metastasis (<pT2 and pN0) [4]. Nonresponding
patients are unlikely to derive clinical benefit, are exposed to
substantial toxicity, and experience a delay in definitive local
therapy [2,3]. Identification of molecular markers of non-
responsiveness is essential for more precise delivery of care.
Recent analyses suggest that specificmutations, especially in
ERCC2, ERBB2, and DNA repair genes, may predict response
to NAC [5–8]. Here we aimed to use RNA expression analysis
for the development of predictive biomarkers.
Recent identification of molecular gene expression
subtypes [9–13] and prior work highlighting the clinical
impact of basal MIBC [14] have advanced our understanding
of the biology of bladder cancer. Molecular classification
provides a framework for further study and has potential
implications for the clinical management of MIBC. Four
different molecular subtyping schemes have been described
[10–13]. Each was developed in different patient popula-
tions using unique genomic platforms, and only one was
based on integrative multiplatform genomic analysis
[10]. Despite these differences, each identifies molecular
phenotypes that share many similarities. They represent a
division into basal and luminal tumors at a higher level, with
different subclassifications that are specific to each system.
Choi et al [11] first introduced the concept that
molecular subtypes may predict response to NAC. In three
cohorts with a total of 100 patients, a subset classified as
having ‘‘p53-like’’ tumors demonstrated a lower response
rate to cisplatin-based combination chemotherapy. This
finding has not been validated in additional larger patient
cohorts and has not been investigated with the othersubtyping methods. Furthermore, none of the four subtyp-
ing models is suitable for clinical implementation because
each requires classification of an entire patient cohort in
order to assign an individual patient sample to a subtype.
In this study, we aimed to correlate large multi-
institutional patient cohort outcomes after NAC with
molecular subtyping of pre-NAC specimens according to
four published classification methods: University of North
Carolina (UNC), MD Anderson Cancer Center (MDA), The
Cancer Genome Atlas (TCGA), and Lund University [10–
13,15]. Moreover, we aimed to develop a single-patient
assay based on transcriptomic analysis of transurethral
resection (TUR) specimens that would be suitable for use in
a clinical laboratory setting.
2. Patients and methods
2.1. Patient populations
For the discovery NAC cohort, 250 consecutive patients from five
institutions were compiled. MIBC (cT2-4aN0-3M0) was diagnosed by
TUR prior to receiving at least three cycles of NAC. For the validation NAC
cohort, 93 consecutive patients with MIBC from two institutions were
selected, whose characteristics were similar to those of the discovery set.
2.2. Tissue sampling and gene expression profiling
Whole transcriptome analysis was performed on formalin-fixed,
paraffin-embedded tumor tissue with [18_TD$DIFF]GeneChip1 [19_TD$DIFF]Human Exon 1.0 ST
Array (Affymetrix) in a Clinical Laboratory Improvement Amendments
(CLIA)-certified laboratory [16]. In total, 223/250 (89%) and 82/93 (88%)
of the discovery and validation NAC cohorts, respectively, passed quality
control (Supplementary Table 1). Microarray data were normalized and
genes summarized using single-channel array normalization [17].
2.3. Datasets from the public domain
For investigation of the prognostic impact of the published methods for
molecular subtyping, the 397 patients without chemotherapy prior to
sample collection from the TCGA bladder urothelial carcinoma were
Table 1 – Patient characteristic table of the cisplatin-based NAC set (n = 269)
Variable Bern NKI UHS UW VGH UCD a EMC a Total p value
n 40 49 22 41 48 26 43 269
Overall survival time
(censored patients)
Median (IQR) 48 (26–73) 46 (31–87) 49 (40–59) 48 (26–61) 31 (13–41) 9 (4–23) 24 (13–36) 35 ( [8_TD$DIFF]16–[9_TD$DIFF]54) –
Age Mean (SD) 64 (10) 57 (11) 67 (12) 62 (11) 61 (9) 65 (8) 59 (13) 61 (11) –
Gender (%) Female 12 (30.0) 17 (34.7) 7 (31.8) 10 (24.4) 14 (29.2) 8 (30.8) 12 (27.9) 80 (29.7) 0.97
Male 28 (70.0) 32 (65.3) 15 (68.2) 31 (75.6) 34 (70.8) 18 (69.2) 31 (72.1) 189 (70.3)
Clinical tumor
stage (%)
T1 1 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) <0.001
T2 4 (10.0) 10 (20.4) 18 (81.8) 20 (48.8) 26 (54.2) 25 (96.2) 17 (39.5) 120 (44.6)
T3 21 (52.5) 26 (53.1) 4 (18.2) 13 (31.7) 19 (39.6) 1 (3.8) 18 (41.9) 102 (37.9)
T4 14 (35.0) 13 (26.5) 0 (0.0) 8 (19.5) 3 (6.2) 0 (0.0) 4 (9.3) 42 (15.6)
NA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (9.3) 4 (1.5)
Clinical lymph node
stage (%)
N0 14 (35.0) 21 (42.9) 20 (90.9) 33 (80.5) 38 (79.2) 0 (0.0) 32 (74.4) 158 (58.7) <0.001 b[7_TD$DIFF]
N1–3 26 (65.0) 28 (57.1) 2 (9.1) 8 (19.5) 10 (20.8) 0 (0.0) 7 (16.3) 81 (30.1)
NA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 26 (100.0) 4 (9.3) 30 (11.2)
Pathological tumor
stage (%)
pT0/is/a 13 (32.5) 24 (49.0) 9 (40.9) 18 (43.9) 19 (39.6) 9 (34.6) 13 (30.2) 105 (39.0) 0.618
pT1 3 (7.5) 2 (4.1) 0 (0.0) 5 (12.2) 2 (4.2) 2 (7.7) 6 (14.0) 20 (7.4)
pT2 8 (20.0) 7 (14.3) 5 (22.7) 6 (14.6) 13 (27.1) 3 (11.5) 5 (11.6) 47 (17.5)
pT3/4 16 (40.0) 15 (30.6) 8 (36.4) 12 (29.3) 14 (29.2) 11 (42.3) 18 (41.9) 94 (34.9)
NA 0 (0.0) 1 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.8) 1 (2.3) 3 (1.1)
Pathological lymph
node stage (%)
pN0 24 (60.0) 28 (57.1) 18 (81.8) 33 (80.5) 41 (85.4) 16 (61.5) 35 (81.4) 195 (72.5) 0.04
pN1–3 16 (40.0) 12 (24.5) 4 (18.2) 8 (19.5) 6 (12.5) 8 (30.8) 7 (16.3) 61 (22.7)
NA 0 (0.0) 9 (18.4) 0 (0.0) 0 (0.0) 1 (2.1) 2 (7.7) 1 (2.3) 13 (4.8)
NAC type (%) GemCis 40 (100.0) 16 (32.7) 22 (100.0) 22 (53.7) 48 (100.0) 19 (73.1) 33 (76.7) 200 (74.3) <0.001
MVAC 0 (0.0) 33 (67.3) 0 (0.0) 19 (46.3) 0 (0.0) 6 (23.1) 5 (11.6) 63 (23.4)
Other 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.8) 5 (11.6) 6 (2.2)
GSC = genomic subtyping classifier; IQR = interquartile range; MVAC = methotrexate, vinblastine, adriamycin, and cisplatin; NA = not applicable;
NAC = neoadjuvant chemotherapy; SD = standard deviation.
a UCD and EMC sets represent blinded and external validation sets not used in discovery of the GSC.
b Excluding UCD due to lack of clinical lymph node status.
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validation of the discovered single-sample classifier was performed only
in those 179 without chemotherapy prior to or after sample collection.
For validation of the discovered classifier, two datasets containing 107
(MDA, GSE48075) and 190 (Lund University, GSE32894) patients with
MIBC who did not receive NAC were downloaded from Gene Expression
Omnibus database.
2.4. Assignment to subtypes
The group from UNC provided the classifiers to assign the samples to
claudin-low, basal, and luminal subtypes [12,15]. The one nearest-
neighbor prediction model from the MDA group assigned the tumors to
basal, p53-like, and luminal subtypes [11]. The model based on
classification to nearest centroids was used to assign the tumors to
the TCGA clusters [10]. The group from Lund provided the centroid
values for each subtype of their original model [13].
2.5. Discovery and validation of the single-sample classifier
A detailed description of the model development, model object, and
score generation code are provided in the supplementary material. In
brief, we developed a single-sample model to predict four subtypes
(claudin-low, basal, luminal-infiltrated, and luminal). A generalized
linear model with elastic net regularization (GLMNET) was trained.
2.6. Statistical analyses
Statistical analyses are described in the supplementary information.3. Results
Clinicopathological details of the discovery and validation
NAC metadatasets are provided in Table 1 and Supplemen-
tary Table 1.3.1. Subtyping calls of the published models in the discovery
NAC dataset
The frequency of each subtype in all pre-NAC samples
(n = 223) was in expected ratios [10,15] (Fig. 1A). Gene
expression of given biological functions confirmed the
concordance between the different subtyping methods
(Fig. 1B, Supplementary Fig. 1, and Supplementary
Table 2). For example, all luminal subtypes showed
higher expression of genes for urothelial differentiation
(Fig. 1B, Supplementary Fig. 2 and Supplementary Fig. 3)
compared with all basal subtypes. T-cell and myeloid cell
signatures were highest in the expected subtypes
(claudin-low [UNC] and cluster IV [TCGA]). Genes from
the extracellular matrix were highly expressed in p53-
like (MDA; Supplementary Fig. 3E) and infiltrated
subtypes (Lund; Fig. 1B). Taken together, these results
demonstrate high concordance between the subtyping
methods, representing the biological spectrum of MIBC as
reported previously.
[(Fig._1)TD$FIG]
Fig. 1 – Molecular subtypes in pre-NAC TURBT samples in discovery NAC cohort. (A) Overview of four previously described bladder cancer subtyping
methods. UNC divides the cancers in two classes, luminal and basal. Claudin [6_TD$DIFF]-low is a subtype within basal that has lost epithelial differentiation and
has a high level of immune infiltration. The MDA subtyping method also divides into basal and luminal tumors, in addition to a third subtype with an
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As recently reported, claudin-low tumors have basal
characteristics with high expression levels of genes indica-
tive of epithelial-to-mesenchymal transition (EMT) and
immune infiltration (Fig. 1C–E, and Supplementary Fig. 4A
and 4C). Tumors in TCGA cluster IV identify a similar subset
of basal tumors: 21/28 cluster IV tumors were labeled
claudin-low. Cluster IV showed enrichment for EMT,
chemokine signaling, and immune infiltration compared
with cluster III tumors (Fig. 1C, 1D, 1F, and Supplementary
Fig. 4B and 4D). Cluster II represents luminal tumors that
are immune infiltrated [18]. Compared with cluster I
tumors, cluster II tumors were EMT-signature positive
and enriched for inflammatory response and chemokine
signaling (Fig. 1F, and Supplementary Fig. 4B and 4E).
3.3. Patient benefit from NAC differs between subtypes
Extravesical extension of residual primary tumor (pT3/4)
after NAC was observed more frequently in claudin-low
(49%), p53-like ([20_TD$DIFF]38%), and cluster II (40%) subtypes. None of
the subtypes was associated with a major response to NAC
(ypT < 2N0) on final pathology (Supplementary Table 3).
Overall survival (OS) varied by molecular subtype and
between non-NAC and NAC patients (Fig. 2). By all
subtyping methods, non-NAC-treated patients (TCGA co-
hort) with basal tumors had worse outcomes compared
with those luminal tumors (Fig. 2). Of both luminal TCGA
clusters, patients with cluster II tumors experienced worse
OS than those with cluster I tumors. Poor OS was also
observed in patients with claudin-low tumors.
The association between subtype and prognosis differed
in our NAC cohort. The most pronounced difference was in
patients with basal or equivalent subtypes (cluster III,
urobasal [Uro] B, and squamous cell carcinoma [SCC]-like),
who experienced a dramatic improvement in OS after NAC
compared with the TCGA patients who received no NAC
(Fig. 2). However, there was no such shift in survival in
patients with claudin-low and cluster IV tumors, indicating
that these patients fared poorly regardless of NAC even
though they are subsets of the basal subtype. Across the
different subtyping methods, patients with luminal or
equivalent tumors had the best OS with or without NAC,
with the exception of cluster II patients, who fared poorly in
both settings, as did patients with p53-like tumors. There
was no noteworthy difference in these trends when
the patients were analyzed according to NAC regimenactive p53 signature (p53 [6_TD$DIFF]-like). The TCGA subtyping defines four clusters that
Lund group discovered five subtypes that can be considered basal (Uro B and S
Heatmap of biologically relevant gene signatures (rows) in pre-NAC TUR samp
provides the subtype calls from each classification system. Claudin-low and clu
cell signatures. Genes expressed in the ECM are expressed in the p53-like and
genomically unstable tumors, while the Uro A subtype expressed an FGFR3 sig
differentiation genes more highly. (C) Heatmap of two bidirectional EMT signa
tumors both were EMT-signature positive, and cluster II tumors showed more
signature in claudin-low versus basal tumors (left) and cluster IV versus III (ri
Differential expression of immune markers (E) CXCL9 and (F) CD8A in the UNC
cluster IV tumors showed the highest expression of immune markers. Referen
ECM = extracellular matrix; EMT = epithelial-to-mesenchymal transition; GU = g
NAC = neoadjuvant chemotherapy; SCC = squamous cell carcinoma; TCGA = The
TURBT = transurethral resection of bladder tumor; UNC = University of North C(gentacibine vs methotrexate, vinblastine, adriamycin, and
cisplatin; Supplementary Fig. 5).
In summary, the differences in OS by subtype and the
apparent impact of NAC suggest that a classification into
four subtypes would have the greatest clinical relevance.
Basal tumors warrant subclassification into tumors without
and with EMT and immune infiltration (ie, basal and
claudin-low, respectively), since NAC appeared to have the
greatest impact on noninfiltrated basal tumors. Luminal
tumors similarly warrant subclassification into tumors
without and with EMT and immune infiltration (ie, luminal
and luminal-infiltrated, respectively), since OS differed
between the two groups.
3.4. Single-sample classifier to predict bladder cancer subtypes
Based on the biological characteristics and different impacts
on clinical outcome, we trained a single-sample genomic
subtyping classifier (GSC) to predict four classes based on the
consensus of the different classification schemes: claudin-
low, basal, luminal-infiltrated, and luminal (Fig. 3A and
Supplementary Table 4). Compared with previously pub-
lished methods, the single-sample GSC was more discrimi-
nate in assigning individual patients to a definitive subtype,
as seen by the number of patients who have a dominant
subtype score (Fig. 3B and Supplementary Fig. 6). Under 10-
fold cross validation, the overall accuracy of GSC assignment
to the four classes in the discovery cohort was 76% (n = 223).
In the validation cohort (n = 82), the accuracy was 73% and
significantly higher (p < 0.001) compared with the no-
information rate of 39% (defined by assignment of the
subtype based on majority class). A multinomial goodness-
of-fit test comparing the predicted probabilities from the
GSCwith the consensus subtype classes using the validation
cohort found that the independent set waswell predicted by
the model and not significantly different compared with the
discovery cohort (p = 0.47). Furthermore, in both the NAC
and the non-NAC cohort (n = 476), consensus subtype
classes (ie, those obtained using previously published
clustering-based approaches) were all predicted with areas
under the curve >0.85 (Fig. 3C).
3.5. Prediction of clinical endpoints using GSC
In both NAC datasets, we used only cases that were treated
with cisplatin-based NAC for analysis of outcomes. The
clinical significance of the predicted classes in the NAC
datasets was compared with an independent non-NACare also basal (clusters III and IV) and luminal (clusters I and II). The
CC-like), luminal (Uro A and genetically unstable), and infiltrated. (B)
les from the discovery cohort. The column annotation across the top
ster IV tumors showed the highest expression of the T-cell and myeloid
infiltrated subtypes. Proliferation markers were highly expressed in
nature. Luminal tumors across subtyping methods express urothelial
tures (Tan et al and Kardos et al [15]). Claudin-low and cluster IV
EMT than cluster I tumors. (D) Enrichment plots of the hallmark EMT
ght). Both subgroups showed significant enrichment of EMT markers.
subtypes (left) and the TCGA clusters (right). The claudin-low and
ce levels: claudin-low, cluster IV. Diff. = differentiation;
enomically unstable; MDA = MD Anderson Cancer Center;
Cancer Genome Atlas; TUR = transurethral resection;
arolina; Uro = urobasal.
[(Fig._2)TD$FIG]
Fig. 2 – Kaplan–Meier estimates of OS according to molecular subtype in the non-NAC (left) and NAC (right) discovery datasets. (A) OS stratified
according to the UNC subtypes. In the non-NAC setting (TCGA, left), patients with claudin-low and basal tumors had worse OS compared to patients
with luminal tumors. The prognostic significance of each subtype changed in the context of NAC (right). While patients with claudin-low tumors still
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Fig. 3 – Discovery and validation of the GSC. (A) Proposed GSC bladder cancer classes derived from a consensus of four models (UNC, MDA, TCGA, and
Lund). Colors indicate each class: claudin-low (gray), basal (red), luminal-infiltrated (light blue), and luminal (dark blue). (B) GSC cross-validation
scores for each sample in the NAC dataset. The vertical bands represent the probability of each sample belonging to each class. The bottom bars
indicate the classes predicted by GSC as well as the consensus classes. (C) Performance of the GSC in the discovery (10-fold cross validation for model
performance) and two independent validation cohorts (NAC validation cohort and non-NAC validation cohort). Across all the cohorts, GSC was able to
predict all subtypes significantly with a high area under the curve (compared with consensus classes). AUC = area under the curve; CI = confidence
interval; Cons. = consensus; GSC = genomic subtyping classifier; inf = infiltrated; MDA = MD Anderson Cancer Center; NAC = neoadjuvant chemotherapy;
TCGA = The Cancer Genome Atlas; UNC = University of North Carolina.
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University of Lund datasets (n = 476). We validated the
relative changes in outcome by GSC subtype in patients
treated with and without NAC (Fig. 4A). Patients with GSChad the worst outcome, the prognosis of patients with basal tumors significan
MDA subtypes. Patients with MDA luminal tumors had the best outcome in bo
patients with p53-like tumors had a significantly shorter OS when compared w
the TCGA clusters. Clusters I and II clearly subdivide luminal tumors into two
prognosis (cluster II)—although neither was affected by NAC. Basal tumors wer
setting, but discrepant responses to NAC. The OS of patients with cluster III tu
cluster IV tumors was poor regardless of NAC. (D) OS stratified according to th
unstable) had the best outcome without (left) and with (right) NAC. The OS of
Uro A tumors in the absence of NAC (left). However, with NAC (right) the outc
proportional hazard ratios. MDA = MD Anderson Cancer Center; NAC = neoadju
carcinoma; TCGA = The Cancer Genome Atlas; UNC = University of North Carolinbasal tumors had a 3-yr OS rate of 49.2% (95% confidence
interval [CI] 39.5–61.2%; p< 0.001) in the non-NAC cohort
compared with 77.8% (95% CI 67.2–90.0%; p< 0.001) in the
NAC cohort.tly improved when treated with NAC. (B) OS stratified according to the
th the non-NAC (left) and NAC (right) settings. In the presence of NAC,
ith patients with MDA luminal tumors. (C) OS stratified according to
subsets—a subset with good prognosis (cluster I) and a subset with poor
e subdivided into two subsets with similar prognosis in the non-NAC
mors was superior when treated with NAC, whereas that of patients with
e Lund subtypes. Patients with luminal tumors (Uro A and genomically
patients with basal tumors (Uro B and SCC-like) was inferior to that of
ome was similar to that in Uro A patients. The p values represent Cox
vant chemotherapy; OS = overall survival; SCC = squamous cell
a; Uro = urobasal.
[(Fig._4)TD$FIG]
Fig. 4 – Clinical significance of GSC with and without cisplatin-based NAC. (A) Kaplan–Meier plots for OS in non-NAC (left) and NAC (right) datasets
stratified according to the classes predicted by GSC. (B) OS of the NAC dataset according to major pathological downstaging stratified by claudin-low
(upper left), basal (upper right), luminal-infiltrated (lower left), and luminal (lower right) subtypes. GSC = genomic subtyping classifier; inf = infiltrated;
NAC = neoadjuvant chemotherapy; OS = overall survival.
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Table 2 – Results of Cox proportional hazard analysis of GSC’s ability to predict overall survival (NAC and non-NAC)
Variable MVA MVAa MVAa
Non-NAC set (n = 476) All NAC set (n = 269) NAC validation set (n = 69)
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Age 1.02 1–1.05 0.066 1.01 0.99–1.04 0.235 0.98 0.93–1.03 0.433
Female (Ref) 1 – 1.000 1 – 1.000 1 – 1.000
Male 0.81 0.53–1.24 0.330 1.12 0.67–1.86 0.661 4.38 0.7–27.52 0.115
Luminal (Ref) 1 – 1.000 1 – 1.000 1 – 1.000
Inf-luminal 2.38 1.33–4.28 0.004 2.46 1.29–4.7 0.006 5.68 0.4–81.3 0.201
Basal 2.22 1.34–3.68 0.002 0.84 0.42–1.68 0.614 0.88 0.16–4.94 0.881
Claudin-low 3.06 1.71–5.47 <0.001 2.16 1.22–3.81 0.008 3.73 0.81–17.25 0.092
CI = confidence interval; GSC = genomic subtyping classifier; HR = hazard ratio; Inf = infiltrated; NAC = neoadjuvant chemotherapy; Ref reference.
a MVA models adjusted for institution and clinical stage.
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stage, age, and gender in the non-NAC cohort, patients with
a GSC basal subtype had a hazard ratio of 2.22 (p = 0.002;
Table 2) for OS compared with the luminal subtype. In
contrast, in the NAC cohort, GSC basal subtype patients did
not fare differently from patients with luminal tumors
(hazard ratio: 0.84, p = 0.61; Table 2). Similar results were
observed when considering only those patients from the
independent NAC dataset (n = 69) not used for GSC model
training (Table 2). Overall, this analysis suggested that the
outcome of patients with basal tumors may improve the
most with NAC.
3.6. NAC survival benefit in GSC basal tumors is independent of
pathological response
As in our analysis using the previously described subtyping
methods, GSC was not significantly associated with a major
pathological response (ie, ypT < 2N0) in the NAC cohort
(Supplementary Tables 3 and 5), even though the major
pathological response was associated with improved OS
(p < 0.001; Supplementary Fig. 7 and Supplementary
Table 6). In an exploratory analysis, we further compared
NAC responders (n = 108) and nonresponders (n = 143) in
each GSC subtype (Fig. 4B). Patients with luminal tumors
who experienced a major response (n = [21_TD$DIFF]48) had a 3-yr OS of
95% (95% CI 89–100%) compared with 58% (95% CI 44–76%)
in nonresponders (n = [22_TD$DIFF]54, p = 0.002; Fig. 4B, lower right). In
stark contrast, patients with GSC basal tumors did not show
any significant differences in OS between major responders
and nonresponders (Fig. 4B, upper right and Supplementary
Table 7). The findings in the luminal-infiltrated and claudin-
low tumors were more similar to the luminal tumors,
although the sample sizes of these subgroupswere too small
and the duration of follow-up too short to allow definitive
conclusions (Fig. 4B, left panels and Supplementary Table 8).
4. Discussion
The recentmolecular characterization ofMIBC, including the
description of subtypes based on gene expression [10–13],
provides a framework for further study of this frequently
lethal malignancy and offers potential biological insight intodifferent clinical phenotypes. One potential immediate
impact of the molecular subtyping is to guide selection of
optimal therapy. This concept was first suggested by Choi
et al [11] in the context of cisplatin-based NAC, and
subsequently by two trials in the context of systemic
checkpoint inhibition [18,19]. Here, we have provided more
evidence in a large patient cohort that outcome after NAC
varies by molecular subtype. Furthermore, we have devel-
oped themethodology for single patient subtyping in a CLIA-
certified laboratory [16], which represents a significant step
toward potential clinical application ofmolecular subtyping.
The most important finding of our study was the relative
shift in outcome by subtype in patients with and without
NAC, albeit based on a comparison across studies. Our
findings support the clinical utility of the four subtypes.
Patients with basal tumors appear to derive the most
benefit from NAC. These highly proliferative basal tumors
demonstrated a poor prognosis when treated with surgery
alone [11], but their prognosis was dramatically improved
in the NAC cohort. Patients with luminal nonimmune-
infiltrated tumors had the best prognosis, irrespective of the
treatment strategy, implying that these patients do not
appear to derive benefit from NAC. The pathological stage
and prognosis of patients with luminal immune-infiltrated
tumors were significantly worse than those with luminal
noninfiltrated tumors. Patients with luminal-infiltrated
tumors appear to have poor prognosis with and without
NAC.
Of a potentially high clinical impact, the patients with
luminal-infiltrated tumors (corresponding to TCGA cluster
II) seemed to benefit most from checkpoint inhibition with
azetolizumab in the IMvigor 210 trial [18]. However, in the
recently published CheckMate 275 trial, patients with
basal tumors appeared to benefit from nivolumab, another
checkpoint inhibitor [19]. Unfortunately, the gene expres-
sion data from neither of these trials have been made
publicly available and the methodology for assignment of
patients to TCGA clusters has not been revealed. Therefore,
it is not currently possible to draw conclusions on the
impact of subtyping on response to checkpoint blockade.
Clinical trials will need to address the relative merit of
NAC and perioperative checkpoint inhibition in these
patients.
E U RO P E AN URO L OGY 7 2 ( 2 0 1 7 ) 5 4 4 – 5 5 4 553We recapitulated similarities between the most recently
discovered claudin-low tumors and TCGA cluster IV
[10,15]. However, while Kardos et al [15] found claudin-
low tumors to be evenly distributed between clusters III and
IV, in our dataset claudin-low tumors were enriched in
cluster IV (75%). Both clusters III and IV are basal tumors
with a strong mesenchymal signature, and both show the
highest degree of immune infiltration. Patients with
claudin-low tumors had the worst prognosis irrespective
of treatment strategy in our analysis, suggesting also that
these patients derived little or no benefit from NAC.
Importantly, although these tumors showed the highest
rate of immune infiltration, the benefit of checkpoint
inhibition was limited in this subtype in the IMvigor 210 [23_TD$DIFF]
and the CheckMate 275 trial [[24_TD$DIFF]18,19]. These patients should
be targeted with priority for inclusion in clinical trials of
novel agents.
Although we observed clear relationships between OS
after NAC and molecular subtypes, we did not observe a
clear effect on pathological response to NAC. The lack of this
expected association [4] may simply be due to sample size
and patient selection, as well as surgical downstaging with
TUR alone. However, our findings resemble those in breast
cancer, where pathological response relates to outcome in
some, but not all, molecular subtypes [20]. In our series, the
lack of association between pathological response and OS
was observed primarily in the basal tumors. Prospective
validation in a larger cohort is required to resolve this issue
in MIBC.
Limitations of this study include the retrospective
design. Moreover, our analysis is also confounded by
comparisons between patient cohorts from different
studies. This makes validation in prospectively collected
cohorts necessary. Since the clinical characteristics of the
cohorts used were different and an unknown proportion of
the Lund dataset was not treated with a curative intent, we
were not able to match non-NAC with NAC cohorts to
perform a direct comparison of the impact of NAC between
subtypes. Nonetheless, the relative differences in OS
between subtypes in the NAC and non-NAC settings
suggest a differential impact of the subtypes on outcome
after NAC.
5. Conclusions
We provide the most compelling data to date that suggest a
relationship between molecular subtypes and response to
cisplatin-based NAC inMIBC.With or without NAC, patients
with luminal tumors do well, implying that NAC is perhaps
unnecessary in this subtype. Immune-infiltrated luminal
tumors appear to have limited benefit from NAC, but have
been shown previously to respond best to checkpoint
inhibition, suggesting an alternative for systemic therapy in
these patients. Claudin-low tumors have theworst outcome
regardless of NAC treatment, and novel therapies are
urgently needed for this patient cohort. The impact of
NAC on OS was greatest in patients with basal tumors,
which raises the hypothesis that these patients should beprioritized for NAC. These findings require prospective
validation before this single-sample classifier can be used in
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